Long-term trials of HRT for cardioprotection - Is this as good as it gets?

Climacteric

Volumn 10, Issue 1, 2007, Pages 1-4

  MacLennan, Alastair H ^a   Sturdee, David W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PLACEBO;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG WITHDRAWAL; EDITORIAL; FRAGILITY FRACTURE; HEALTH CARE COST; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; STATISTICAL SIGNIFICANCE; SYMPTOM; THROMBOEMBOLISM; UTERUS BLEEDING;

CARDIOVASCULAR DISEASES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; REFUSAL TO PARTICIPATE;

EID: 33847133807     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130601135847     Document Type: Editorial

References (18)

1. Phillips LS, Langer RD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005;83:558-66
2. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006;15:35-44
3. Pines A, Sturdee DW, Birkhauser M on behalf of the International Menopause Society. More data on hormone therapy and coronary heart disease: Comments on recent publications from the WHI and Nurses' Health Study. Climacteric 2006;9:75-6
4. Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med 2006;21:363-6
5. Salpter SR, Walsh ME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone therapy in younger and older women. J Gen Intern Med 2004;19:791-804
6. Koh KK. Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy? Int J Cardiol 2003;87:1-8
7. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No CD002978. DOI: 10.1002/14651858.CD002978.pub2
8. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial plus progestin. Maturitas 2006;55:103-5
9. MacLennan AH, Sturdee DW. Towards safer women, safer doses, safer routes and safer timing of administration of safer menopausal therapies. Climacteric 2005;8:1-2
10. Sturdee DW, MacLennan AH. Prevention of osteoporosis is still a valid aim for hormone therapy. Climacteric 2005;8:97-8
11. MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy use over a decade in an Australian population. Climacteric 2002;5:351-6
12. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414-19
13. Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise - was it inevitable? Climacteric 2002;5:317-25
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
15. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 2004;291:1701-12
16. Shapiro S. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy; detection bias and resolution of discrepant findings in two Women's Health Initiative studies. Climacteric 2006;9:416-20
17. Harman SM, Brinton E, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3-12
18. Sturdee DW, MacLennan AH. Should epidemiology, the media and quangos determine clinical practice? Climacteric 2004;7:1-2